Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review …
S Elshafie, R Trivedi, LA Villa‐Zapata, RL Tackett… - Cancer, 2025 - Wiley Online Library
Background Despite significant advances in breast cancer control and survival with
endocrine therapies (ETs), treatment utilization and outcomes in developing countries have …
endocrine therapies (ETs), treatment utilization and outcomes in developing countries have …
Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer
SM Chiwambutsa, O Ayeni, N Kapungu… - Clinical …, 2023 - Wiley Online Library
Clinical outcomes of tamoxifen (TAM) treatment show wide interindividual variability.
Comedications and genetic polymorphisms of enzymes involved in TAM metabolism …
Comedications and genetic polymorphisms of enzymes involved in TAM metabolism …
Antitumor effect of Iso-mukaadial acetate on MCF-7 breast cancer mice xenograft model
PP Raphela-Choma, R Lukhwareni, MBC Simelane… - Scientific Reports, 2024 - nature.com
Antitumor drugs used today have shown significant efficacy and are derived from natural
products such as plants. Iso-mukaadial acetate (IMA) has previously been shown to possess …
products such as plants. Iso-mukaadial acetate (IMA) has previously been shown to possess …
Pharmacogenetics and Pharmacokinetics of Tamoxifen in a Zimbabwean breast cancer cohort
BT Mbavha, RS Thelingwani… - British Journal of …, 2023 - Wiley Online Library
Tamoxifen is the most used hormonal therapy for oestrogen receptor‐positive breast cancer.
CYP2D6 is the main enzyme in the metabolic pathway of tamoxifen to endoxifen. Variations …
CYP2D6 is the main enzyme in the metabolic pathway of tamoxifen to endoxifen. Variations …
Perspectives on common chronic diseases in adult cancer patients in South Africa
There is a rising noncommunicable disease (NCD) burden in low-and middle-income
countries. Sub-Saharan Africa (SSA) bears a higher burden than the global average with …
countries. Sub-Saharan Africa (SSA) bears a higher burden than the global average with …
PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients—a South African cohort study
B Phakathi, T Dix-Peek, E Van Den Berg… - Breast Cancer Research …, 2023 - Springer
Purpose Treatment decision making for patients with breast cancer increasingly depends on
analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer …
analysis of markers or systems for estimating risk of breast cancer recurrence. Breast cancer …
Access to and Utilization of Endocrine Therapy Among Breast Cancer Survivors in Botswana
JR Wester, RB Wagner, B Motladiile, I Nkele… - JCO Global …, 2024 - ascopubs.org
PURPOSE Breast cancer (BC) is the most common female cancer worldwide, and the
burden is increasing across sub-Saharan Africa. For women with hormone receptor–positive …
burden is increasing across sub-Saharan Africa. For women with hormone receptor–positive …
Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast …
Purpose: We aimed to evaluate for associations between HIV status, psychosocial factors,
and adjuvant endocrine therapy (AET) adherence in South African (SA) women with …
and adjuvant endocrine therapy (AET) adherence in South African (SA) women with …
Pharmacogenetics: uncovering the complex relationship between HIV and non-adherence among South African breast cancer patients treated with tamoxifen
KC Nthontho, L Tawe, GM Paganotti - Breast Cancer Research and …, 2023 - Springer
With great interest, we read the paper titled “The impact of HIV on non-adherence for
tamoxifen among women with breast cancer in South Africa” by Ayeni et al.[1]. We would like …
tamoxifen among women with breast cancer in South Africa” by Ayeni et al.[1]. We would like …